Description
There is much discussion about emerging markets in in vitro diagnostics, especially the BRIC nations – Brazil, Russia, India and China. Which companies have been successful in these markets and how have they accomplished it? What kind of realistic growth can marketers expect by selling products in these areas? This report is intended to provide an overview of trends and developments in the IVD industry as it applies to emerging markets and the BRIC countries in particular.
A Realistic Look at the Market for IVD in New, Emerging Markets
A good number of reports on the BRIC and emerging markets have been published. Most of these focus on quantitative data such as the number of labs and hospitals, product registration regulations, and import taxes and conditions. Too many of them perhaps present merely a growth scenario without presenting the challenges the nations face and the challenges companies face when entering these markets. This report provides much of this information with its objective overview of the market for in vitro diagnostics in selected countries. This report also explores the opportunities that specific developing countries offer to IVD companies.
Kalorama also attempts to add some realistic aspects of working in a foreign country that are more qualitative in nature. Thus the report explores some of the cultural aspects of how the market for clinical diagnostics may evolve in a selection of emerging markets including the BRIC countries.
Useful Information for Business Planning
The discussion of each of the BRIC markets begins with a short introduction to the country and follows with a SWOT analysis of the market for IVDs. The SWOT analysis provides positive and negative aspects of market conditions. The author has decided to include positive and negative aspects of certain factors in the same SWOT category. The factors are classed positive or negative according to the strength of current market conditions. This is done to make the analysis comprehensive and easier to read.
The report covers data trends and issues, including:
- Healthcare trends and metrics in each country
- Physician Office Testing (POL) in BRIC Countries
- Disease Trends (Diabetes, Cancer, Allergy, Emerging Viruses)
- Lab Systems in BRIC Countries
- SWOT Analysis for Each BRIC Nation, Including:
- Strengths – factors that make the country attractive for IVD companies
- Weaknesses that form barriers to entry and success such as health insurance coverage, regulatory affairs and distribution issues
- Country elements that provide testing Opportunities
- Threats – a look at the competition and incumbents
- Key Companies Operating in Each Country
- Research and High Technology in BRIC Countries
- Other Trends (Insurance, Medical Tourism,
Recession Effects)
Market and economic trends are discussed from the point of view of their present and potential impact and there is a focus on the mix of economics, healthcare and diagnostics that may evolve in these countries.
Beyond BRICWith all the attention directed at the BRIC countries, there is a tendency to think that they are the only prospects for IVD market growth and development. The fact is that some of the same trends – a growing middle class, mix of infectious and non-communicable diseases and government supported healthcare – are prevalent in many countries in Eastern Europe and Africa. We provide as an example three non-BRIC nations: Turkey, Poland and Nigeria, where IVD may flourish in the future.
From Kalorama Information, a Respected Source for IVD Market AnalysisAuthored by Shara Rosen, R.T. MBA, the author of the seven editions of
The Worldwide Market for In Vitro Diagnostics, this report explores some of the quantitative and qualitative aspects of emerging markets but leaves conclusions up to the readers, who can best judge how their individual company culture and strategic aspirations fit with prospects in emerging countries. The information contained here provides an overview of the general economic and infrastructure information related to emerging markets.
The information presented in this report is derived from publicly available information sources such as company, government, and medical organization reports. It is combined with expert analysis based on the author’s industry knowledge combined with literature searches and interviews with industry professionals and experts in in vitro diagnostics.
All Kalorama reports advertise the single user price. Use is limited to one user. We also feature department and global pricing for reports that we be utilized by more than one user at your company. Please consult ask your sales representative or select the correct license on our website.
For Kalorama’s take on the healthcare news of the week, based on our analysis of healthcare markets, follow Kalorama Information’s Key Point Blog at http://kaloramakeypoint.blogspot.com/
Table of Contents
TABLE OF CONTENTS
CHAPTER ONE: EXECUTIVE SUMMARY
- Scope and Methodology
- Emerging Market Trends
- World Demand for Diagnostics
CHAPTER TWO: INTRODUCTION
- Background
- Population Trends and Disease Demographics
- Disease Trends
- Diabetes
- Cancer
- Allergy
- Emerging Viruses
- Market Segment Opportunities
- Physician Office Testing (POL)
- Lab Systems
- Research and High Technology
- Insurance Trends
- Medical Tourism
- Recession Effects
CHAPTER THREE: OVERVIEW AND BRIC COMPARISON
- Background
- The BRIC Metrics
- Available Market
- Culture of Paying for Healthcare
- Capacity to Serve
- IVD Spending
- China and India – The BRIC Engines
CHAPTER FOUR: CHINA: MARKET TRENDS/DEMAND ANALYSIS
- Introduction
- Strengths – Factors That Make the Country Attractive
- Weaknesses – Factors That Offer Barriers to Market Success and Entry
- Insurance
- Regulatory Affairs
- Distribution Issues
- Opportunities – Elements That Provide Opportunity
- Threats – competition and incumbent players
- The Market
- International IVD Companies
- Bayer Diabetes Care
- Biohit Oy
- Cogenics (now part of Danaher)
- Eiken Chemical Co., Ltc
- Fenwal, Inc.
- IRIS International, Inc.
- Luminex Corporation
- MedMira
- m-u-t AG
- PerkinElmer
- Phadia AB
- QIAGEN N.V.
- Quest Diagnostics
- Quintiles
- Roche Diagnostics
- SuperNova Diagnostics, Inc.
- China-based Companies
- Autobio Group
- Beijing Genome Institute (BGI)
- Bio-Asia Diagnostics
- CapitalBio Corporation
- Caretium Medical Instruments
- Chemtron Biotech Co. Ltd
- China Health Labs & Diagnostics Ltd.
- China Medical Technologies
- China Sky One Medical, Inc.
- Hai Kang Life Corporation
- Mindray Medical International Limited
- Motic
- ProGenTech Limited
- Runbio Biotech Co. Ltd.
- Shanghai Kehua Bio-Engineering
- Vita Genomics
CHAPTER FIVE: INDIA: MARKET TRENDS/DEMAND ANALYSIS
- Introduction
- Strengths – factors that make the country attractive
- No Centralized Decision Makers
- Insurance
- Regulatory Affairs
- Distribution Issues
- Opportunities – elements that provide opportunity
- Threats – competition and incumbent players
- The Market
- International IVD Companies
- Biomagnetics Diagnostics Corp.
- DiaGenic
- Novartis Diagnostics
- PerkinElmer
- Phadia AB
- QIAGEN N.V.
- Quest Diagnostics
- Quintiles
- Radient Pharmaceuticals Corp.
- India-Based Companies
- 3B BlackBio India Biotech
- Agappe Diagnostics
- AGD Biomedicals Pvt. Ltd.
- Avesthagen Limited
- Diagnova
- J.Mitra & Co. Pvt Ltd
- ROBONIK INDIA PVT LTD
- Span Diagnostics Ltd.
- Transasia Bio-Medicals Ltd.
- Trivitron Group
- The Tulip Group
- Vimta Labs
CHAPTER SIX: BRAZIL: MARKET TRENDS/DEMAND ANALYSIS
- Introduction
- Strengths – factors that make the country attractive
- Weaknesses – factors that offer barriers to market success and entry
- Insurance
- Regulatory Affairs
- Distribution
- Opportunities – elements that provide opportunity
- Threats – competition and incumbent players
- The Market
- International IVD Companies
- Agendia B.V.
- AnaSpec, Inc.
- Axela Inc.
- Chembio Diagnostics Inc.
- Fluidigm Corporation
- Genomic Health, Inc.
- Hemagen Diagnostics, Inc
- Phadia AB
- Brazil-based Companies
- Bio-Manguinhos/FioCruz
- BIOTÉCNICA Indústria e Comércio Ltda
- CELM – Companhia Equipadora De Laboratorios Modernos
- Doles Reagentes
- Ebram Productos Laboratorias
- Gold Analisa
- Hemogram Indústria e Comercio de Produtos Hospitalares
- Katal Biotechnologica/Interteck
- Laborlab
- Wama Diagnostica
CHAPTER SEVEN: RUSSIA: MARKET TRENDS/DEMAND ANALYSIS
- Introduction
- Strengths – Factors that make the Country Attractive
- Weaknesses – Factors that Offer Barriers to Market Success and Entry
- Insurance
- Regulatory Affairs
- Distribution Issues
- Opportunities – Elements That Provide Opportunity
- Threats – Competition and Incumbent Players
- The Market
- International IVD Companies
- Arrayit Corp.
- Biohit Oy
- Russia-based Strength
- Alkor Bio
- Biola
- Dialat Ltd.
- Evrogen JSC
- InterLabService Ltd. (ILS)
- Olveks Diagnostikum
- Technomedica
- Vital Diagnostics SPb
- Xema-Medica Co., Ltd.
CHAPTER EIGHT: NATIONS OTHER THAN BRIC
- Introduction
- Turkey
- Poland
- Nigeria
CHAPTER NINE: CONCLUSION
- Introduction
- Insurance
- Intellectual Property Protection
- Regulatory Affairs & Distribution
- Market Opportunities
TABLE OF EXHIBITS
CHAPTER ONE: EXECUTIVE SUMMARY
- Figure 1-1 IVD Market in BRIC Nations
- Table 1-1: In Vitro Diagnostic Reagent, BRIC countries 2009-2014, $ million
- Table 1-2: Market Conditions in Developing Countries
- Table 1-3: Worldwide In Vitro Diagnostic Reagent Sales by Country/Region 2009-2014,
CHAPTER TWO: INTRODUCTION
- Table 2-1: Selected Disease Statistics, Worldwide, 2008
- Table 2-2: Elderly Support Ratio in Selected Countries (2050)
- Table 2-3: Overview of Physician Office Labs by Country
- Table 2-4: Labs in the BRIC Countries
- Table 2-5: Medical Cost Increases, Worldwide, 2006-2008
CHAPTER THREE: OVERVIEW AND BRIC COMPARISON
- Table 3-1: Available Market Data, 2009
- Table 3-2: Healthcare Expenditure History
- Table 3-3: Healthcare Infrastructure Capacity
- Table 3-4: IVD Expenditure per person, 2009
- Table 3-5: BRIC IVD sales, 2009-2014
- Table 3-6: Infrastructure data for major markets, 2005-2006
CHAPTER FOUR: CHINA: MARKET TRENDS/DEMAND ANALYSIS
- Table 4-1: Selected Disease Prevention Programs
- Table 4-2: Selected Preventative Medicine Opportunities
- Table 4-3: IVD Market Segmentation, China 2009, percent dollar sales
- Table 4-4: Company Market Share Data, 2009
- Table 4-5: Selected IVD Manufacturers in China
CHAPTER FIVE: INDIA: MARKET TRENDS/DEMAND ANALYSIS
- Table 5-1: Key Drivers for Healthcare in India
- Table 5-2: IVD Market Segmentation, India 2009, percent dollar sales
- Table 5-3: Company Market Share Data, 2009
CHAPTER SIX: BRAZIL: MARKET TRENDS/DEMAND ANALYSIS
- Table 6-1: Brief History of Brazil’s Health Reform (1988-2009)
- Table 6-2: IVD Market Segmentation, Brazil 2009 (Chemistry, Immunoassays, Hematology/Coag, Molecular, Other)
- Table 6-3: Company Market Share Data, 2009
CHAPTER SEVEN: RUSSIA: MARKET TRENDS/DEMAND ANALYSIS
- Table 7-1: Market Share of Imported Products, by country 2009
CHAPTER EIGHT: NATIONS OTHER THAN BRIC
- Table 8-1:Country Metrics: Turkey, Poland, Nigeria
- Table 8-2: Major Private Networks in Poland
CHAPTER NINE: CONCLUSION
- Table 9-1: Selected Advanced IVDs in Demand
